Hep C Virus - Migenix issues update on clinical programs

Migenix issues update on clinical programs
San Diego Daily Transcript via Yahoo! News - Jan 23 2:56 PM
Migenix Inc. (Pink: MGIFF.PK, News), a clinical-stage developer of drugs for infectious and degenerative diseases, released an update of ongoing clinical programs on Monday.Save to My Web

VX-950, Investigational Oral Hepatitis C Protease Inhibitor, Demonstrates Rapid and Dramatic Reduction in Viral Levels
[Press Release] PR Newswire via Yahoo! Finance - Jan 09 4:02 AM
New data announced today by Vertex Pharmaceuticals Incorporated show that VX-950, an investigational oral hepatitis C virus protease inhibitor, dosed in combination with pegylated interferon alfa-2a , achieved a rapid and dramatic reduction in plasma viral RNA levels in patients with chronic genotype 1 HCV infection.Save to My Web

InterMune downgraded to "sell" - update
New Ratings - Jan 11 2:51 AM
NEW YORK, January 11 (newratings.com) - Analysts at Stifel Nicolaus & Company downgrade InterMune Inc ( ITMN.NAS ) from "hold" to "sell."Save to My Web

Peregrine Accelerates Tarvacin HCV Study
AP via Yahoo! Finance - Jan 18 5:28 AM
Biopharmaceutical company Peregrine Pharmaceuticals Inc. said Wednesday that it is accelerating its program to test its cancer drug Tarvacin for the treatment of hepatitis C.Save to My Web